Tetsuhito Koijima, Nagoya University Graduate School of Medicine, Pathophysiological Laboratory Sciences, 1-1-20 Daiko-Minami Higashi-ku, Nagoya Aichi 461-8673, Japan, Tel.: +81 52 719 3153, Fax: +81 52 719 3153, E-mail:
Thromb Haemost. 2016 Nov 30;116(6):1022-1031. doi: 10.1160/TH16-03-0223. Epub 2016 Sep 8.
Antithrombin (AT) and thrombomodulin (TM) play important roles in the process of natural anticoagulation in vivo. Recently, we reported that the prothrombin Yukuhashi mutation (p.Arg596Leu) was associated with AT and TM resistance-related thrombophilia. To assess the AT and TM resistances associated with other missense mutations by single base substitution in the Arg596 codon, we generated recombinant variants (596Gln, 596Trp, 596Gly, and 596Pro) and investigated the effects on AT and TM anticoagulant functions. All variants except 596Pro were secreted in amounts comparable to that of the wild-type but exhibited variable procoagulant activities. After a 30-minute inactivation by AT, the relative residual activity of wild-type thrombin decreased to 15 ± 4.0 %, in contrast to values of all variants were maintained at above 80 %. The thrombin-AT complex formation, as determined by enzyme-linked immunosorbent assay, was reduced with all tested variants in the presence and absence of heparin. In the presence of soluble TM (sTM), the relative fibrinogen clotting activity of wild-type thrombin decreased to 16 ± 0.12 %, whereas that of tested variants was 37 %-56 %. In a surface plasmon resonance assay, missense Arg596 mutations reduced thrombin-TM affinity to an extent similar to the reduction of fibrinogen clotting inhibition. In the presence of sTM or cultured endothelial-like cells, APC generation was enhanced differently by variant thrombins in a thrombin-TM affinity-dependent manner. These data indicate that prothrombin Arg596 missense mutations lead to AT and TM resistance in the variant thrombins and suggest that prothrombin Arg596 is important for AT- and TM-mediated anticoagulation.
抗凝血酶 (AT) 和血栓调节蛋白 (TM) 在体内天然抗凝过程中发挥重要作用。最近,我们报道了凝血酶原 Yukuhashi 突变 (p.Arg596Leu) 与 AT 和 TM 抵抗相关的血栓形成倾向有关。为了评估其他单个碱基替换引起的 Arg596 密码子错义突变与 AT 和 TM 抵抗的关系,我们生成了重组变体(596Gln、596Trp、596Gly 和 596Pro),并研究了它们对 AT 和 TM 抗凝功能的影响。除 596Pro 外,所有变体的分泌量与野生型相当,但表现出不同的促凝活性。在 AT 30 分钟失活后,野生型凝血酶的相对残留活性降低至 15±4.0%,而所有变体的活性均保持在 80%以上。酶联免疫吸附试验 (ELISA) 测定的凝血酶-AT 复合物形成在存在和不存在肝素的情况下均减少。在存在可溶性 TM (sTM) 的情况下,野生型凝血酶的相对纤维蛋白原凝固活性降低至 16±0.12%,而测试变体的活性为 37%-56%。在表面等离子体共振 (SPR) 测定中,错义 Arg596 突变以与纤维蛋白原凝固抑制降低相似的程度降低了凝血酶-TM 亲和力。在 sTM 或培养的内皮样细胞存在下,不同变体凝血酶以依赖于凝血酶-TM 亲和力的方式以不同方式增强 APC 的生成。这些数据表明,凝血酶原 Arg596 错义突变导致变体凝血酶中的 AT 和 TM 抵抗,并表明凝血酶原 Arg596 对 AT 和 TM 介导的抗凝作用很重要。